Imunon, Inc. Files Q3 2024 10-Q
Ticker: IMNN · Form: 10-Q · Filed: Nov 7, 2024 · CIK: 749647
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting
TL;DR
Imunon (formerly Celsion) filed its Q3 2024 10-Q. Check financials.
AI Summary
Imunon, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Celsion Corp, is in the pharmaceutical preparations industry. Financial details and specific operational updates for the third quarter of 2024 are presented in this filing.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational status of Imunon, Inc. for the third quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Imunon faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Imunon, Inc. (company) — Filer of the 10-Q
- Celsion Corp (company) — Former name of Imunon, Inc.
- 20240930 (date) — End of the reporting period
- 20241107 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is September 30, 2024.
What was Imunon, Inc. formerly known as?
Imunon, Inc. was formerly known as Celsion Corp.
What is the Standard Industrial Classification (SIC) code for Imunon, Inc.?
The SIC code for Imunon, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
On what date was this 10-Q filed?
This 10-Q was filed on November 7, 2024.
In which state was Imunon, Inc. incorporated?
Imunon, Inc. was incorporated in Delaware (DE).
Filing Stats: 4,416 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2024-11-07 09:00:46
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
Filing Documents
- form10-q.htm (10-Q) — 1289KB
- ex10-5.htm (EX-10.5) — 10KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 8KB
- ex10-5_001.jpg (GRAPHIC) — 506KB
- ex10-5_002.jpg (GRAPHIC) — 501KB
- ex10-5_003.jpg (GRAPHIC) — 442KB
- ex10-5_004.jpg (GRAPHIC) — 475KB
- ex10-5_005.jpg (GRAPHIC) — 582KB
- ex10-5_006.jpg (GRAPHIC) — 486KB
- ex10-5_007.jpg (GRAPHIC) — 493KB
- ex10-5_008.jpg (GRAPHIC) — 499KB
- ex10-5_009.jpg (GRAPHIC) — 381KB
- ex10-5_010.jpg (GRAPHIC) — 118KB
- 0001493152-24-043931.txt ( ) — 11532KB
- imnn-20240930.xsd (EX-101.SCH) — 33KB
- imnn-20240930_cal.xml (EX-101.CAL) — 47KB
- imnn-20240930_def.xml (EX-101.DEF) — 129KB
- imnn-20240930_lab.xml (EX-101.LAB) — 340KB
- imnn-20240930_pre.xml (EX-101.PRE) — 258KB
- form10-q_htm.xml (XML) — 788KB
SIGNATURES
SIGNATURES 38 Cautionary Note Regarding Forward-Looking Statements This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q, including, without limitation, any projections of earnings, revenue or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, pre-clinical development, clinical trials, manufacturing and commercialization), uncertainties and assumptions regarding any continuing impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, any statements concerning proposed drug candidates, potential therapeutic benefits, or other new products or services, any statements regarding future economic conditions or performance, any changes in the course of research and development activities and in clinical trials, any possible changes in cost and timing of development and testing, capital structure, financial condition, working capital needs and other financial items, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified using terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that our expectations are based on reasonable assumptions within the bounds of our knowledge of our industry, business, and operations, we cannot guarantee that actual results will not differ materially from our expectations. Our future financial condition and results of operations, as well as any forward-looking st